Pompe Disease

May 21, 2025

Unveiling Lysosomal Storage Disorders: Exploring Rare Diseases Impacting Millions Worldwide

Feb 11, 2025

Immix Bio’s NXC-201 Gets FDA RMAT for AL Amyloidosis; Biodexa’s eRapa Wins Fast Track for Familial Adenomatous Polyposis; AbbVie’s EMBLAVEO Approved for Complicated Intra-Abdominal Infections; Insmed’s Brensocatib Gains Priority Review for Bronchiectasis; Aro Bio’s ABX1100 IND Cleared for Pompe Disease

Nov 01, 2024

5 Promising Pompe Disease Drugs in Early-stage Development

Oct 16, 2024

Transforming Pompe Disease Care: Latest Innovations and Strategic Advances in Treatment

Sep 30, 2024

The Transforming Pompe Disease Treatment Landscape in Emerging Markets

Sep 30, 2024

Pompe Disease Treatment Landscape

Sep 30, 2024

Pompe Disease: Causes, Symptoms, Diagnosis, Pathology, Current Marketed and Emerging Drugs in the Pipeline

Sep 30, 2024

Advances in Pompe Disease Treatment: From ERT to New Therapies

Sep 30, 2024

Navigating Challenges in Pompe Disease Treatment and Research in Eastern Europe

Jan 24, 2023

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

Newsletter/Whitepaper